It doesn't take a trained physician to know that a disease needs to be diagnosed to
be treated. And it doesn't take an economist to know that a disease cannot be diagnosed
if the required tools are unaffordable or impractical. The absence of early diagnosis
and treatment is particularly problematic for infectious disease, where the lack of
early treatment or isolation can result in an epidemic.
Given the technological requirements, diagnosis and monitoring of HIV infection is
problematic in resource-poor areas. The advent of rapid tests for diagnosing HIV infection
represents one part of the solution. Less clear is how patients diagnosed with HIV
infection will be monitored, given the importance of CD4 cell counts. A decrease in
CD4+ T lymphocytes—a critical immune cell infected by HIV—is one of the hallmarks
of HIV disease, and CD4+ cell number is a key factor in determining disease progression
and monitoring treatment. The methods for determining CD4+ cell numbers are technically
complex, expensive, and not easily transportable. These factors severely limit the
ability to monitor HIV disease in locations where resources, training, and mobility
are limited.
Lymphocytes are characterized by cell surface markers; thus, CD4+ lymphocytes express
the CD4 marker on their surface. Antibody probes that specifically recognize this
and other cell surface markers (such as CD8, which distinguishes that lymphocyte population
from CD4+ lymphocytes, and CD3, which is a marker for all T lymphocytes) are used
to count and differentiate various cell populations. By labeling cells with fluorescently
tagged antibodies that recognize one or more cell surface molecules, the relative
and absolute numbers of specific cells can be determined by a technique called flow
cytometry. The labeled cells are passed through the flow cytometer, where the fluorescent
probes are activated by lasers in a manner that can be read by specific detectors.
The CD4+ cell number is directly correlated with the resultant fluorescent intensity
and other light scatter properties. The problem is that flow cytometry requires costly
reagents and substantial technical expertise—factors that limit its use in less developed
areas.
Taking advantage of advances in microfluidics, digital imaging, and cell analysis,
William Rodriguez and colleagues now report on a way to count CD4+ cells in a relatively
quick, easy, and affordable manner. Small volumes of blood (an amount that could be
obtained by a finger prick as opposed to drawing blood from a vein) are labeled as
in flow cytometry, but with far less of the expensive reagents. Microfiltration allows
the labeled CD4+ cells to be captured and separated from red blood cells, another
simplification relative to flow cytometry. Digital images of the labeled cells, obtained
by digital fluorescence microscopy, are then analyzed by newly developed software
that can distinguish the CD4, CD8, and CD3 labels, thus allowing determination of
absolute CD4+ counts, CD4+ percentages, and CD4+:CD8+ lymphocyte ratios.
Rodriguez et al. found that this new method was less accurate than flow cytometry
for determining absolute CD4+ lymphocyte counts above 500 cells/mm3 (levels that are
typically not relevant for monitoring HIV-infected individuals). But the method was
as accurate as flow cytometry at clinically relevant levels of CD4+ cells for HIV-infected
adult individuals. Although only a small number of pediatric patients were examined
(and thus statistical significance could not be ascertained), the method appears to
be also effective in determining CD4+ lymphocyte percentages in children.
The detection system used in the present report is a tabletop instrument that serves
as a prototype for a fully portable handheld model, which is now under development.
After some modest training, such a tool should allow a variety of health-care workers
in remote areas to accurately analyze the CD4+ status of HIV-infected patients (the
basis for treatment decisions) locally. In an accompanying Perspective discussing
this new tool (DOI: 10.1371/journal.pmed.0020214), Zvi Bentwich argues that before
it is ready for widespread use, several issues still need to be resolved, such as
its final cost and its applicability to pediatric patients. “Despite these reservations,”
he says, “the authors of this study should be commended for addressing an extremely
important issue and developing this novel approach for counting CD4 in patients with
HIV.”